Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) Equity Average (2016 - 2026)

Pharma-Bio Serv's Equity Average history spans 14 years, with the latest figure at $11.1 million for Q1 2026.

  • For Q1 2026, Equity Average fell 13.84% year-over-year to $11.1 million; the TTM value through Jan 2026 reached $11.1 million, down 13.84%, while the annual FY2025 figure was $12.8 million, 14.12% down from the prior year.
  • Equity Average reached $11.1 million in Q1 2026 per PBSV's latest filing, down from $11.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $18.2 million in Q1 2022 to a low of $11.1 million in Q1 2026.
  • Average Equity Average over 5 years is $14.7 million, with a median of $15.1 million recorded in 2024.
  • Peak YoY movement for Equity Average: fell 29.4% in 2022, then fell 0.57% in 2023.
  • A 5-year view of Equity Average shows it stood at $16.4 million in 2022, then dropped by 1.2% to $16.2 million in 2023, then fell by 15.2% to $13.7 million in 2024, then decreased by 13.0% to $11.9 million in 2025, then fell by 7.08% to $11.1 million in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Equity Average are $11.1 million (Q1 2026), $11.9 million (Q4 2025), and $12.0 million (Q3 2025).